<?xml version="1.0" encoding="UTF-8"?>
<ref id="B148-biomedicines-08-00060">
 <label>148.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Gollamudi</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Ghalib</surname>
    <given-names>M.H.</given-names>
   </name>
   <name>
    <surname>Desai</surname>
    <given-names>K.K.</given-names>
   </name>
   <name>
    <surname>Chaudhary</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Wong</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Einstein</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Coffey</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Gill</surname>
    <given-names>G.M.</given-names>
   </name>
   <name>
    <surname>Mettinger</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Mariadason</surname>
    <given-names>J.M.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Intravenous administration of Reolysin
   <sup>Â®</sup>, a live replication competent RNA virus is safe in patients with advanced solid tumors
  </article-title>
  <source>Investig. New Drugs</source>
  <year>2010</year>
  <volume>28</volume>
  <fpage>641</fpage>
  <lpage>649</lpage>
  <pub-id pub-id-type="doi">10.1007/s10637-009-9279-8</pub-id>
  <pub-id pub-id-type="pmid">19572105</pub-id>
 </element-citation>
</ref>
